LIAN - Nanobiotix partners with J&J's Janssen for radiotherapy treatment
2023-07-18 10:26:11 ET
- LianBio ( NASDAQ: LIAN ) partner Nanobiotix has inked a deal with Johnson & Johnson ( NYSE: JNJ ) division Janssen Pharmaceutica on the development of radioenhancer NBTXR3.
- Janssen is receiving a worldwide license for co-development and commercialization of the candidate except in areas where licensing has already been granted to LianBio ( LIAN ). These countries are China, Hong Kong, Macau, Taiwan, Thailand, South Korea, and Singapore.
- NBTXR3, composed of functionalized hafnium oxide nanoparticles, is given via a one-time intratumoral injection and activated by radiotherapy. It is designed to bring about tumor cell death when activated by radiotherapy.
- LianBio ( LIAN ) and Nanobiotix are currently enrolling patients in a phase 3 trial of NBTXR3 with or without Erbitux (cetuximab) versus radiotherapy with or without cetuximab in individuals with locally advanced head and neck squamous cell carcinoma.
- Seeking Alpha's Quant Rating views LianBio ( LIAN ) as a hold.
For further details see:
Nanobiotix partners with J&J's Janssen for radiotherapy treatment